[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-detail":3},{"lang":4,"article":5,"alternate":19,"related":20,"latest":29},"en",{"id":6,"slug":7,"title":8,"content":9,"summary":10,"thumbnail":11,"metaDescription":12,"metaKeywords":13,"created":14,"modified":14,"author":15,"authorEn":15,"categoryId":16,"commentCount":17,"thumbnailToContent":18},12687,"retatrutide-triumph2-obesity-zfqk","A Weekly Shot That Matches a Year of Bariatric Surgery","\u003Cp style=\"margin:0 0 18px;\">One weekly injection just matched the first two years of bariatric surgery: \u003Cstrong>27.6 kg off — 23.4% of body weight — in 80 weeks\u003C\u002Fstrong>, in people whose BMI starts above 35. Surgery typically buys 20–35% over the same window. This drug is still in Phase 3.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">On September 30, at the 62nd EASD annual meeting in Milan, Eli Lilly unveiled the full results of retatrutide's TRIUMPH-2 trial — and \u003Ci>The Lancet\u003C\u002Fi> published them the same day.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cimg src=\"\u002Fattachment\u002F20261002\u002F07f040078cd7450981f553888580569c.webp\" alt=\"img_01.webp\">\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cstrong>TRIUMPH-2 (NCT05929079)\u003C\u002Fstrong> randomized about 1,152 participants with obesity or overweight plus type 2 diabetes to weekly retatrutide 4 mg, 9 mg, 12 mg, or placebo, for 80 weeks. Average weight loss: \u003Cstrong>13.5 kg (12.7%), 20.6 kg (19.1%), and 22.5 kg (20.8%)\u003C\u002Fstrong> for the three doses.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">The sicker group did even better. In participants with baseline BMI ≥ 35, the 12 mg arm lost \u003Cstrong>27.6 kg (23.4%)\u003C\u002Fstrong> — the range surgery delivers in its first two years, without the scalpel.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cimg src=\"\u002Fattachment\u002F20261002\u002Fec92cecf94e14967a9f0ba6cac5bfcc4.webp\" alt=\"img_02.webp\">\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">Blood sugar followed. A1C fell \u003Cstrong>1.4%, 1.5%, and 1.6%\u003C\u002Fstrong> across doses, and up to \u003Cstrong>40.0% of participants reached A1C < 5.7%\u003C\u002Fstrong> — the normal glucose range.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">The same top dose produced a list of metabolic wins, each measured: triglycerides \u003Cstrong>−39.5%\u003C\u002Fstrong>, non-HDL cholesterol \u003Cstrong>−19.6%\u003C\u002Fstrong>, systolic blood pressure \u003Cstrong>−10.8 mmHg\u003C\u002Fstrong>, waist circumference \u003Cstrong>−16.9 cm\u003C\u002Fstrong>, and high-sensitivity C-reactive protein \u003Cstrong>−58.3%\u003C\u002Fstrong>.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cimg src=\"\u002Fattachment\u002F20261002\u002F957c20f405c8469c9d0908620ea487b3.webp\" alt=\"img_03.webp\">\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">Why would one molecule do all this? Retatrutide is the first triple receptor agonist in clinical development, engaging GIP, GLP-1, and glucagon (GCG) receptors together. GLP-1 pushes insulin secretion and suppresses GCG; GIP adds insulin when glucose is high; the GCG arm is the wildcard — it raises energy expenditure and drives fat breakdown, while GIP buffers the glucose spike GCG can cause. Three mechanisms, one injection.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cimg src=\"\u002Fattachment\u002F20261002\u002Fa4f69fc71e9b40b2b2d378d5ab8bbbd6.webp\" alt=\"img_04.webp\">\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">Safety looked tolerable: the commonest events were diarrhea, nausea, constipation, decreased appetite, and vomiting, mostly mild to moderate; discontinuation ran 3.8%, 11.6%, and 7.7% across doses versus 4.9% on placebo.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">The pipeline behind it is already crowded. Novo Nordisk's CagriSema — cagrilintide plus semaglutide — beat tirzepatide head-to-head in REIMAGINE 5 (12.4% vs 9.1% weight loss) and cut 21.0% versus placebo's 2.0% in REDEFINE 9. Meanwhile Eli Lilly quietly ended an early-stage program (LY4064912), Novo returned TransCon semaglutide rights, and Pfizer wrote off part of its $10 billion Metsera deal.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">\u003Cimg src=\"\u002Fattachment\u002F20261002\u002F848bc0286df545ebade6eaf0c64dc897.webp\" alt=\"img_05.webp\">\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">This is what a winner's market looks like: \u003Cstrong>20% weight loss no longer moves the needle\u003C\u002Fstrong>, and drugs get cut not because they fail but because continuing is uneconomical. After semaglutide, tirzepatide, and now retatrutide, no single selling point — weight loss, oral dosing, durability, muscle preservation, safety — guarantees success. The next winner probably needs all of them.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">Lilly plans to file retatrutide in the U.S. in the first quarter of next year, with more Phase 3 readouts — knee osteoarthritis pain, obstructive sleep apnea, chronic low-back pain, cardiorenal outcomes, and MASH — due over the next twelve months. It could become the first approved triple agonist.\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">Curious what obesity actually looks like under a microscope? Retatrutide makes fat cells surrender their lipid droplets — you can watch fat cells and lipid droplets in a human adipose tissue specimen under a real microscope, including a \u003Cstrong>human adipose tissue specimen\u003C\u002Fstrong> where fat cells and lipid droplets are clearly visible. Search \"WWAI\" in your app store and download it today.\u003C\u002Fp>\n\u003Cdiv class=\"dp-template-card\" style=\"border-radius:8px;box-shadow:0 2px 8px rgba(0,0,0,0.1);margin:10px 0;max-width:100%;overflow:hidden;width:100%;\">\n \u003Ca style=\"display:block;text-decoration:none;\" href=\"https:\u002F\u002Fyun-hub.chat\u002Flink\u002F?app=wwai&clickid=stellarx&dplink=qid%3Dq618\" target=\"_blank\">\u003Cimg class=\"image_resized\" style=\"display:block;height:auto;max-width:100%;width:100%;\" src=\"\u002Fattachment\u002F20260824\u002F6d6978c8815843e99369c46ff316e5bd.png\" alt=\"6d6978c8815843e99369c46ff316e5bd\">\n  \u003Cbutton style=\"align-items:center;background-color:#13d605;border-radius:0 0 4px 4px;border-style:none;color:#ffffff;cursor:pointer;display:flex;font-family:Times New Roman;font-size:14px;height:40px;justify-content:center;padding:0;width:100%;\">Enter WWAI Discover the Secrets\u003C\u002Fbutton>\u003C\u002Fa>\n\u003C\u002Fdiv>\n\u003Cp style=\"margin:0 0 18px;\">References:\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">1. U.S. National Library of Medicine, ClinicalTrials.gov, TRIUMPH-2 (NCT05929079): https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05929079\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">2. Eli Lilly investor release, orforglipron 17.2 mg indirect comparison: https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">3. Novo Nordisk, CagriSema U.S. filing and REIMAGINE 5 news: https:\u002F\u002Fwww.novonordisk.com\u002Fcontent\u002Fnncorp\u002Fglobal\u002Fen\u002Fnews-and-media\u002Fnews-and-ir-materials\u002Fnews-details.html?id=916774\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">4. T.D. Müller, C. Clemmensen, B. Finan, R.D. DiMarchi, M.H. Tschöp, \"Anti-Obesity Therapy: from Rainbow Pills to Polyagonists,\" Pharmacological Reviews 70(4):712–746, 2018: https:\u002F\u002Fpharmrev.aspetjournals.org\u002Fcontent\u002F70\u002F4\u002F712\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 18px;\">All illustrations are AI-generated.\u003C\u002Fp>\n\u003Cp style=\"color:#111;margin:28px 0 8px;\">\u003Cstrong>Related reading\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 20px;\">\u003Ca style=\"color:#111;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fthyroid-nodule-biology\">\u003Cimg class=\"image_resized\" style=\"border-radius:8px;display:block;height:auto;margin-bottom:6px;max-width:520px;width:100%;\" src=\"https:\u002F\u002Fcdn.banyunjuhe.com\u002Fattachment\u002F20260926\u002Fc692aaf26f724affae2a2016cb40a159.png\" alt=\"A 1 cm Thyroid Nodule Turned Out to Be Cancer While a Bigger…\">\u003C\u002Fa>\u003Cbr>\u003Ca style=\"color:#0b6cb0;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fthyroid-nodule-biology\">\u003Cstrong>A 1 cm Thyroid Nodule Turned Out to Be Cancer While a Bigger…\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 20px;\">\u003Ca style=\"color:#111;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fmoth-larvae-chewing-cars\">\u003Cimg class=\"image_resized\" style=\"border-radius:8px;display:block;height:auto;margin-bottom:6px;max-width:520px;width:100%;\" src=\"https:\u002F\u002Fcdn.banyunjuhe.com\u002Fattachment\u002F20260926\u002F554c67bfe7fe4467985e06b238d7e818.png\" alt=\"Why Are Mysterious Round Holes Appearing on Parked Cars? The…\">\u003C\u002Fa>\u003Cbr>\u003Ca style=\"color:#0b6cb0;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fmoth-larvae-chewing-cars\">\u003Cstrong>Why Are Mysterious Round Holes Appearing on Parked Cars? The…\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp style=\"margin:0 0 20px;\">\u003Ca style=\"color:#111;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fsugar-free-mooncake-blood-sugar\">\u003Cimg class=\"image_resized\" style=\"border-radius:8px;display:block;height:auto;margin-bottom:6px;max-width:520px;width:100%;\" src=\"https:\u002F\u002Fcdn.banyunjuhe.com\u002Fattachment\u002F20260926\u002Fa8d067036ae849758bd8f1ff2df65b6c.png\" alt=\"Why 'Sugar-Free' Mooncakes Can Still Spike Your Blood Sugar\">\u003C\u002Fa>\u003Cbr>\u003Ca style=\"color:#0b6cb0;text-decoration:none;\" href=\"https:\u002F\u002Fstellarx.tech\u002Farticle\u002Fsugar-free-mooncake-blood-sugar\">\u003Cstrong>Why 'Sugar-Free' Mooncakes Can Still Spike Your Blood Sugar\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>","","\u002Fattachment\u002F20261002\u002Fcd00597fc91a4b1baf9697c072a4117d.webp","A weekly shot matched bariatric surgery: 27.6 kg off in 80 weeks in adults with BMI over 35. Phase 3 data of the first triple-receptor GLP-1 drug, in Lancet.","stellarx, wwai, GLP-1, retatrutide, weight loss, bariatric surgery, obesity, type 2 diabetes, triple agonist, The Lancet","2026-10-02 18:25:39","Science Guide Wwai",77,0,false,null,{"prev":21,"next":25},{"id":22,"slug":23,"title":24,"categoryId":16},12688,"potato-staple-weight-loss-potassium-zxqm","Why a Potato Staple Diet Melts Weight Without Calorie Math",{"id":26,"slug":27,"title":28,"categoryId":16},12686,"som-tam-involution-diet-nqwk","Thailand's National Salad Is the Ultimate 'Involution' Food",[30,35,40,45],{"id":31,"slug":32,"title":33,"thumbnail":34,"categoryId":16},12700,"human-fur-clothing-evolution-sqrz","Why Humans Are the Only Animals That Need Clothes","\u002Fattachment\u002F20261002\u002Fb31b02de36e4466c80eba6aeb3c4c5db.webp",{"id":36,"slug":37,"title":38,"thumbnail":39,"categoryId":16},12699,"pomelo-low-calorie-fall-fruit-bxwq","A Whole 1.25 kg Pomelo Has Only 280 kcal. Here's Why.","\u002Fattachment\u002F20261002\u002Fdd4a6aacec8e45a0b60a730b785dc885.webp",{"id":41,"slug":42,"title":43,"thumbnail":44,"categoryId":16},12698,"salmonella-contamination-food-safety-hqwk","Salmonella Is Everywhere. Here's How It Gets Into Your Food","\u002Fattachment\u002F20261002\u002Fe9794747ac274244896cd160b39fb201.webp",{"id":46,"slug":47,"title":48,"thumbnail":49,"categoryId":16},12697,"dry-eye-meibomian-gland-oil-xkmv","Your Dry Eyes Aren't Thirsty — They're Out of Oil","\u002Fattachment\u002F20261002\u002F7ea41af72a454602a61e79297a1ece03.webp"]